As per the letter attached

Scheme filed with the NCLTDemerger ratio announcedStrategic Transactions View source PDF Explain this filing

LYKALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.6%Reaction day

₹62.00

prior close

₹58.99

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-3.3% vs market

Pharmaceuticals peers, median of 165sector+0.2%-2.8% vs sector

On the reaction day the stock moved 3.3 pts less than Nifty Microcap 250 and 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+0.9

15m

+0.9

30m

+1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.6+0.7-3.3+0.2-2.8

Next day

-7.3+0.7-7.9-0.1-7.1

-7.9+0.0-7.9-0.3-7.6

-5.6-1.1-4.6-1.3-4.3

-6.5+0.0-6.5-1.2-5.3

-6.7+0.3-7.0-1.5-5.2

+1.7+1.1+0.6-0.6+2.2

15d

+12.9+4.9+8.1-0.5+13.4

+17.7+5.3+12.3+2.6+15.0

+3.5+6.9-3.3+4.1-0.6

+20.2+11.9+8.3+7.1+13.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lyka Labs reported its Q4 and FY26 audited financial results. The company recorded an impairment loss of Rs. 2301.44 Lakhs on its investment and loans in subsidiary Lyka BDR International Limited due to continuous operational losses and eroding net worth. Standalone revenue from operations for FY26 was Rs. 13,469.74 Lakhs, down from Rs. 13,735.74 Lakhs in FY25. The company reported a net loss of Rs. 14.40 Lakhs on standalone basis. The Board also announced a Record Date of June 4, 2026 for the Scheme of Amalgamation where Lyka Exports Limited (Transferor) will merge into Lyka Labs (Transferee). Under this NCLT-approved scheme, shareholders of Lyka Exports will receive 23 equity shares of Lyka Labs for every 100 shares held. The 47th AGM is scheduled for August 10, 2026.

Likely market impact

The impairment charge reflects losses in the subsidiary and will impact FY26 earnings, though the clean audit opinion provides some comfort. The upcoming merger with Lyka Exports (NCLT approved March 2026) will dilute existing shareholders by approximately 4.63 lakh new shares and may create near-term stock volatility around the record date.